E Fürer - Concepedia

Author

E Fürer

Swiss Vaccine Research Institute

Also Known As

E Furer, E Fürer, E. Furer, E. FÜRER, E. Fürer, Emil Furer, Emil Fürer, Fürer, Emil, Stanley J. Cryz

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

Swiss Vaccine Research Institute Walter Reed Army Institute of Research University of Bern

About

E Fürer is an author at Swiss Vaccine Research Institute specializing in medicine, infection control, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	37	2K
2	Health Sciences	10	10	760
3	Allergy	7	7	332
4	Biochemistry	6	6	466
5	Natural Sciences	2	2	59

E Fürer

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Role of lipopolysaccharide in virulence of Pseudomonas aeruginosa Stanley J. Cryz, Tyrone L. Pitt, E Fürer, Infection and Immunity Gram-negative BacteriologyBiosynthesisHealth SciencesBiochemistryVirulence Factor	1984	199
Immunity in Experimental Salmonellosis II. Basis for the Avirulence and Protective Capacity of <i>gal</i> E Mutants of <i>Salmonella typhimurium</i> R. Germanier, E Fürer Infection and Immunity Lipopolysaccharide CompositionMicrobial PathogensImmunologyGlycobiologyBacteriology	1971	122
Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide Stanley J. Cryz, E Fürer, R. Germanier Infection and Immunity ImmunotoxicologyAntibiotic AdjuvantImmunologyAntimicrobial ChemotherapyDrug Resistance	1983	118
Vaccination of Cystic Fibrosis Patients Against Pseudomonas aeruginosa Reduces the Proportion of Patients Infected and Delays Time to Infection Aloïs B. Lang, A Rüdeberg, Martin H. Schöni, The Pediatric Infectious Disease Journal	2004	100
Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans. Stanley J. Cryz, E Fürer, Alan S. Cross, Journal of Clinical Investigation VaccinationPs-toxin A ConjugateMicrobial ToxinAntimicrobial SusceptibilityVaccine Development	1987	100
Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome‐Formulated Influenza Vaccine Containing<i>Escherichia coli</i>Heat‐Labile Toxin as a Mucosal Adjuvant Reinhard Glück, Robert Mischler, Peter Durrer, The Journal of Infectious Diseases Young AdultsElderly SubjectsImmunologyFlu VaccinationMucosal Adjuvant	2000	100
Safety and immunogenicity of Pseudomonas aeruginosa conjugate A vaccine in cystic fibrosis U. B. Schaad, J Wedgwood, Anna Ruedeberg, The Lancet VaccinationMucosal VaccinationImmunologyPseudomonas Aeruginosa ConjugateMicrobiology	1991	83
Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults S J Cryz, Myron M. Levine, James B. Kaper, Vaccine VaccinationVaccine SafetyPreventive MedicineVaccine TrialVaccine Efficacy	1990	80
Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide Stanley J. Cryz, E Fürer, R. Germanier Infection and Immunity Humoral ResponseImmunologySerotype SpecificImmunotherapyMurine Burn	1984	76
Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice Stanley J. Cryz, E Fürer, R. Germanier Infection and Immunity Multiple InjectionsReproducible ModelSimple ModelKlebsiella PneumoniaeImmunology	1983	69

Page 1